AC
NVO

Arrow Capital’s Novo Nordisk NVO Stock Holding History

Arrow Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.79M Buy
+100,000
New +$4.3M 4.08% 11
2026
Q1 		– Sell
-130,000
Closed -$6.61M – 25
2025
Q4 		$6.61M Buy
130,000
+60,000
+86% +$3.07M 6.34% 8
2025
Q3 		$5.87M Buy
+70,000
New +$4.1M 3.15% 20
2025
Q1 		– Sell
-30,000
Closed -$2.58M – 37
2024
Q4 		$2.58M Buy
+30,000
New +$3.24M 2.36% 21

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Arrow Capital's NVO Position: Q2 2026 in Review

Arrow Capital opened a new position in Novo Nordisk (NVO) in Q2 2026: 100,000 shares worth $4.79M. The stake represents 4.08% of the portfolio and ranks #11 among its holdings. This is a return to the name: Arrow Capital previously reported a position in NVO as recently as Q4 2025.

Arrow Capital first reported a position in NVO in Q4 2024 and has held it in 4 quarters since. The position peaked at $6.61M in Q4 2025. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Arrow Capital held 100,000 shares of Novo Nordisk worth $4.79M as of Q2 2026.
  • Novo Nordisk was a new Arrow Capital position in Q2 2026.
  • Novo Nordisk made up 4.08% of Arrow Capital's portfolio in Q2 2026, its #11 holding.
  • Arrow Capital first reported a position in Novo Nordisk in Q4 2024 and has held it in 4 quarters since.
  • Arrow Capital's Novo Nordisk position peaked at $6.61M in Q4 2025.
  • 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Arrow Capital's 13F filing for Q2 2026, filed 5 Aug 2026.